ATE342729T1 - Modifizierter tumor-nekrosefaktor - Google Patents

Modifizierter tumor-nekrosefaktor

Info

Publication number
ATE342729T1
ATE342729T1 AT98904563T AT98904563T ATE342729T1 AT E342729 T1 ATE342729 T1 AT E342729T1 AT 98904563 T AT98904563 T AT 98904563T AT 98904563 T AT98904563 T AT 98904563T AT E342729 T1 ATE342729 T1 AT E342729T1
Authority
AT
Austria
Prior art keywords
tnf
necrosis factor
tumor necrosis
modified tumor
range
Prior art date
Application number
AT98904563T
Other languages
English (en)
Inventor
Mike A Clark
Original Assignee
Phoenix Pharmacologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Pharmacologics Inc filed Critical Phoenix Pharmacologics Inc
Application granted granted Critical
Publication of ATE342729T1 publication Critical patent/ATE342729T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98904563T 1997-01-15 1998-01-15 Modifizierter tumor-nekrosefaktor ATE342729T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3552197P 1997-01-15 1997-01-15
US681098A 1998-01-14 1998-01-14

Publications (1)

Publication Number Publication Date
ATE342729T1 true ATE342729T1 (de) 2006-11-15

Family

ID=26676095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904563T ATE342729T1 (de) 1997-01-15 1998-01-15 Modifizierter tumor-nekrosefaktor

Country Status (11)

Country Link
US (1) US7785579B2 (de)
EP (1) EP1007082B1 (de)
JP (1) JP4295831B2 (de)
CN (1) CN1168495C (de)
AT (1) ATE342729T1 (de)
AU (1) AU725133B2 (de)
CA (1) CA2277757C (de)
DE (1) DE69836222T2 (de)
DK (1) DK1007082T3 (de)
ES (1) ES2275300T3 (de)
WO (1) WO1998031383A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158923B1 (de) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-uricase Konjugate und Verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
CN1315351A (zh) * 2000-03-24 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人一种组织或发育阶段特异转录因子相关因子11和编码这种多肽的多核苷酸
WO2002067857A2 (en) * 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
EP1234583A1 (de) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
EP1857462B9 (de) * 2005-02-18 2013-02-13 Nof Corporation Polyoxyalkylenderivat
DK3321359T3 (da) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc Variante former af uratoxidase og anvendelse deraf
WO2008051178A2 (en) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
CN102807973A (zh) 2005-04-11 2012-12-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
KR100886783B1 (ko) 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
CN101837130B (zh) * 2009-03-20 2013-10-23 北京大学 聚乙二醇-二肽-抗肿瘤药物复合物及其用途
US20100284962A1 (en) * 2009-05-06 2010-11-11 Oncopharmacologics, Inc. Modified tumor necrosis factor-beta
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
WO2014151865A1 (en) 2013-03-14 2014-09-25 Ran Biotechnologies, Inc. Methods and materials for detection of biologicals
EP3575397A1 (de) 2013-03-14 2019-12-04 Ran Biotechnologies, Inc. Verfahren und materialien zur erfassung von mikroorganismen
CN105294852B (zh) * 2015-10-27 2019-06-07 岳阳新华达制药有限公司 聚乙二醇与肿瘤坏死因子α或其类似物的偶联物及其医药用途
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AU2017248264B2 (en) 2016-04-07 2020-01-30 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP3538135A4 (de) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC Kombinationstherapien von prednison- und uricase-molekülen und deren verwendung
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5447722A (en) 1983-12-12 1995-09-05 University Of Manitoba Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
JPH04502011A (ja) 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド ポリペプチド誘導体
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Also Published As

Publication number Publication date
JP2001511784A (ja) 2001-08-14
CA2277757A1 (en) 1998-07-23
US7785579B2 (en) 2010-08-31
CA2277757C (en) 2008-09-16
DE69836222D1 (de) 2006-11-30
JP4295831B2 (ja) 2009-07-15
AU6241098A (en) 1998-08-07
CN1243444A (zh) 2000-02-02
US20060222626A1 (en) 2006-10-05
WO1998031383A1 (en) 1998-07-23
EP1007082B1 (de) 2006-10-18
EP1007082A4 (de) 2004-05-12
DK1007082T3 (da) 2007-02-19
ES2275300T3 (es) 2007-06-01
CN1168495C (zh) 2004-09-29
AU725133B2 (en) 2000-10-05
DE69836222T2 (de) 2007-11-15
EP1007082A1 (de) 2000-06-14

Similar Documents

Publication Publication Date Title
DE69836222D1 (de) Modifizierter tumor-nekrosefaktor
EP0933995B8 (de) Verfahren zur behandlung von endothelialen verletzungen
PT943326E (pt) Composicao em po para administracao nasal
NZ212632A (en) Tumor necrosis factor, its preparation and its use
CA2265708A1 (en) Lipoxin compounds and their use in treating cell proliferative disorders
NZ337845A (en) Non-antigenic branched polymer conjugates
CA2291065A1 (en) Raf kinase inhibitors
DK524187A (da) Aminosyrechelaterede midler til udlevering til specifikke biologiske vaevssteder
DE69737995D1 (de) INSULINPREPARATION MIT MAnnitol
EA200100954A1 (ru) Производные камптотецина, обладающие противоопухолевой активностью
EP0293852A3 (de) Organopolysiloxanzusammensetzungen, die funktionelle alpha,beta-ungesättigte Carbonylgruppen enthalten
IL133311A0 (en) Imidazolyl-cyclic acetals
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
ATE66614T1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
GR3015431T3 (en) Use of acetyl L-carnitine in the therapeutic treatment of coma.
FI880944A7 (fi) Yhdistelmäterapia, jossa käytetään antituumori-immunotoksiineja yhdessä tuumorin nekroositekijän kanssa.
NO984052D0 (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
DE69130063D1 (de) Antivirales arzneimittel enthaltend prostratin
NO995944D0 (no) Anti-arrytmisk blanding og fremgangsmåter for behandling
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
KR900700124A (ko) 흑색종 치료용 il-2 및 dtic의 치료 조성물
ES2036526T3 (es) Composiciones de interferon.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007082

Country of ref document: EP

EEIH Change in the person of patent owner